Drug Profile
Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical
Alternative Names: Arcatus; ARVN 001; CLS triamcinolone acetonide; CLS-1001; CLS-1003; CLS-1004; CLS-TA; suprachoroidal CLS-TA; triamcinolone acetonide injectable suspension - Bausch Health Companies; Triamcinolone acetonide ophthalmic suspension; XIPERE; ZUPRATALatest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Clearside Biomedical
- Developer Arctic Vision; Bausch Health Companies; Clearside Biomedical
- Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Uveitis
- Phase II Diabetic macular oedema
- No development reported Ocular inflammation
- Discontinued Retinal oedema
Most Recent Events
- 30 Nov 2023 Phase-I clinical trials in Diabetic macular oedema in Asia, Australia, India, New Zealand, South Korea (Intraocular) (Clearside Biomedical Pipeline; November 2023)
- 30 Nov 2023 Phase-III clinical trials in Uveitis in New Zealand, Asia, South Korea (Intraocular) (Clearside Biomedical Pipeline; November 2023)
- 04 Oct 2023 Arctic Vision completes enrolment in its phase III trial for Uveitis in China (Intraocular)